Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)

• ClinicalTrials.gov Identifier: NCT01955421
• Recruitment Status: Unknown
• First Posted: October 7, 2013
• Last Update Posted: July 3, 2015
• Sponsor: Sun Yat-sen University
• Information provided by (Responsible Party): Li Zhang, Sun Yat-sen University

Study Description

Brief Summary:

This study is a multicenter, randomized, open-label Phase II trial that compares reduced dose erlotinib 100mg daily and standard dose gefitinib 250mg daily in patients with advanced non-small cell lung cancer who harbor EGFR mutations. The primary endpoint is disease control rate (DCR) and the key secondary endpoint is progression free survival (PFS). A total of 224 eligible patients will be randomized to receive either erlotinib 100mg daily or gefitinib 250mg daily in a 1:1 ratio until patients experience disease progression. Independent assessment of the major endpoints will be completed in a treatment-blinded manner. Randomization will be stratified based on treatment-lines (first-line vs. maintenance vs. second-line therapy). Tumor response and progression will be assessed according to RECIST 1.1.

Condition or disease	Intervention/treatment	Phase
Advanced Stage Non Small Cell Lung Cancer	Drug: Erlotinib 100mg qd; Drug: Gefitinib 250mg qd	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 224 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized, Open-label Phase II Trial of Erlotinib 100mg Daily Versus Gefitinib 250mg Daily in Patients With Advanced Non-small Cell Lung Cancer Who Harbor EGFR Mutations.
• Study Start Date: July 2013
• Estimated Primary Completion Date: June 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: Erlotinib100; Patients will be randomized to buy and receive erlotinib 100mg qd.	Drug: Erlotinib 100mg qd
Experimental: Gefitinib250; Patients will be randomized to buy and receive gefitinib 250mg qd.	Drug: Gefitinib 250mg qd

Outcome Measures

Primary Outcome Measures :

1. disease control rate [ Time Frame: 2 years ]

Secondary Outcome Measures :

1. progression free survival [ Time Frame: 2 years ]
2. adverse events [ Time Frame: 2 years ]
   rash, diarrhea, ILD, etc.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Diagnosis of advanced stage NSCLC (stage IIIB or IV) which is confirmed by histology or cytology methods.
2. Harboring a PCR-confirmed activating mutation of EGFR, including an exon 19 deletion or an exon 21 L858R point mutation.
3. Measurable disease according to RECIST1.1.
4. Eastern Cooperative Oncology Group (ECOG) score of 0-2

5. Adequate organ function, defined as all of the following:

   1. LVEF >50% or within institution normal values.
   2. Absolute neutrophil count (ANC)>1500/mm3.
   3. Platelet count >75,000/mm3
   4. Estimated creatinine clearance>45m1/min.
   5. Total bilirubin<1.5 times institutional ULN (Patients with Gilbert's Syndrome total bilirubin must be <4 times institutional ULN).
   6. Aspartate amino transferase (AST) or alanine amino transferase (ALT) < three times the institutional upper limit of normal (ULN) (if related to liver metastases<five times institutional ULN).
6. Recovered from any previous therapy related toxicity to ≤CTCAE Grade 1 at study entry (except for stable sensory neurupethy ≤CTCAE Grade 2 and alopecia).
7. Ability to take oral medication in the opinion of the investigator.
8. Age ≥ 18 years.
9. Written informed consent that is consistent with ICH-GCP guidelines.

Exclusion Criteria:

1. Prior treatment with EGFR directed small molecules or antibodies.

2. Radiotherapy within 4 weeks prior to randomization, except as follows:

   1. Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to randomization
   2. Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling.
3. Active brain metastases (stable for <4 weeks, symptomatic, or leptomeningeal disease). Dexamethasone therapy will be allowed if administered as a stable dose for at least 4 weeks before randomization.
4. Any other current malignancy or malignancy diagnosed within the past three (3) years (other than basal-cell carcinoma of the skin, in situ cervical cancer, in situ prostate cancer).
5. Known pre-existing interstitial lung disease.
6. Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g. Crohn's disease, malabsorption or CTC grade >2 diarrhoea of any aetiology, based on investigator assessment.
7. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3 (Refer to Appendix 10.4), unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to randomisation.
8. Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
9. Women of child-bearing potential and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended. Adequate methods of contraception and women of Child-Beanng Potenial are discussed in Section 4.2.2.3.
10. Female patients of childbearing potential (see Section 4.2.2.3) who are nursing or are pregnant.
11. Patients unable to complv with the protocol in the opinion of the investigator.
12. Active hepatitis B infection (detined as presence of Hepatitis B DNA), active hepatitis C infection (defined as vresence of Hepatitis C RNA) and/or known HIV carrier.
13. Known or suspected active drug or alcohol abuse in the opinion of the investigator.
14. Requirement for treatment with any of the prohibited concomitant medications listed in Section 4.2.3.
15. Any contraindications for therapy with gefitinib or erlotinib.
16. Known hypersensitivity to erlotinib, gefitinib or the exipients of any of the trial drugs
17. Major surgery within 4 weeks of starting study treatment.
18. Use of any investigational drug within 4 weeks of randomisation (unless a longer time period is required by local regulations or by the guidelines for the investigational product).

Contacts and Locations

Locations

China, Guangdong

Department of Medical Oncology, Cancer Center of Sun Yat-Sen University; Recruiting

Guangzhou, Guangdong, China, 510060

Contact: Wenhua Liang, MD 8613710249454 liangwh@sysucc.org.cn

Principal Investigator: Li Zhang, MD

Sub-Investigator: Wenhua Liang, MD

Sponsors and Collaborators

Sun Yat-sen University

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zhao S, Zhang Z, Fang W, Zhang Y, Zhang Z, Hong S, Ma Y, Zhou T, Yang Y, Huang Y, Zhao H, Zhang L. Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study. Front Oncol. 2020 Nov 10;10:587849. doi: 10.3389/fonc.2020.587849. eCollection 2020.

• Responsible Party: Li Zhang, Professor, Sun Yat-sen University
• ClinicalTrials.gov Identifier: NCT01955421
• Other Study ID Numbers: E100VG250; Tarceva100vsIressa250 ( Registry Identifier: Tarceva100vsIressa250 )
• First Posted: October 7, 2013
• Last Update Posted: July 3, 2015
• Last Verified: July 2015

Keywords provided by Li Zhang, Sun Yat-sen University:

NSCLC; stage IIIB; stage IV); confirmed by histology or cytology methods; Harboring a PCR-confirmed activating mutation of EGFR, including an exon 19 deletion or an exon 21 L858R point mutation

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Erlotinib Hydrochloride; Gefitinib; Tyrosine Kinase Inhibitors; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents